In yesterday’s Wall Street session, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) shares traded at $0.41, up 36.86% from the previous session.
MRNS stock price is now -73.59% away from the 50-day moving average and -89.81% away from the 200-day moving average. The market capitalization of the company currently stands at $22.31M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $6, Oppenheimer recently Upgraded its rating from Perform to Outperform for Marinus Pharmaceuticals Inc (NASDAQ: MRNS). , while ‘Robert W. Baird’ rates the stock as ‘Neutral’
In other news, Pfanstiel Steven, CFO AND COO sold 4,657 shares of the company’s stock on Aug 05 ’24. The stock was sold for $5,262 at an average price of $1.13. Upon completion of the transaction, the CFO AND COO now directly owns 79,773 shares in the company, valued at $32706.93. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 05 ’24, CHIEF COMMERCIAL OFFICER Shafer Christina sold 3,820 shares of the business’s stock. A total of $4,355 was realized by selling the stock at an average price of $1.14. This leaves the insider owning 67,406 shares of the company worth $27636.46. A total of 12.99% of the company’s stock is owned by insiders.
During the past 12 months, Marinus Pharmaceuticals Inc has had a low of $0.28 and a high of $11.26. The fifty day moving average price for MRNS is $1.53382 and a two-hundred day moving average price translates $3.977355 for the stock.
The latest earnings results from Marinus Pharmaceuticals Inc (NASDAQ: MRNS) was released for 2024-06-30. The net profit margin was -493.14% and return on equity was -2986.55% for MRNS. The company reported revenue of $8.06 million for the quarter, compared to $6.08 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 32.48 percent.
